Trial Profile
An Open-Label, Phase I Study of Systemic Hedgehog Pathway Antagonist, GDC-0449, in Patients With Locally Advanced or Metastatic Solid Tumours That Are Refractory to Standard Therapy or For Whom No Standard Therapy Exists
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer; Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- Sponsors Genentech
- 07 May 2010 Actual end date ( Nov 2009) added as reported by ClinicalTrials.gov.
- 07 May 2010 Actual end date ( Nov 2009) added as reported by ClinicalTrials.gov.
- 17 Sep 2009 Results in basal cell carcinoma expansion cohort published in NEJM.